{"id":"NCT00731549","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia","officialTitle":"A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2013-11","completion":"2013-11","firstPosted":"2008-08-11","resultsPosted":"2014-11-11","lastUpdate":"2014-11-26"},"enrollment":1081,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Aripiprazole IM Depot","otherNames":["Oral Aripiprazole"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"To evaluate the overall effectiveness of aripiprazole intramuscular (IM) depot as maintenance treatment in patients with schizophrenia.","primaryOutcome":{"measure":"Percentage of Stable Participants at Baseline Who Remained Stable at Endpoint (Last Visit).","timeFrame":"Baseline to Week 52/Last visit","effectByArm":[{"arm":"Aripiprazole 400/300 mg IM Depot","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":214,"countries":["United States","Argentina","Australia","Austria","Belgium","Bulgaria","Chile","Croatia","Estonia","Finland","France","Hungary","India","Malaysia","Mexico","Norway","Philippines","Poland","Puerto Rico","Romania","Russia","Serbia","Slovakia","South Africa","South Korea","Spain","Taiwan","Thailand"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":95,"n":1081},"commonTop":["Headache","Nasopharyngitis","Anxiety","Insomnia"]}}